Skip to main content
Erschienen in: Endocrine 1/2017

22.03.2016 | Pros and Cons in Endocrine Practice

Premixed insulin regimens in type 2 diabetes: pros

verfasst von: Maria Ida Maiorino, Giuseppe Bellastella, Katherine Esposito, Dario Giugliano

Erschienen in: Endocrine | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Because of the increasing prevalence of type 2 diabetes, the need to intensify treatment to manage hyperglycemia is expanding. Premixed insulin regimens were designed to maximize patient convenience and reduce the number of daily injections required by providing both rapid-acting and intermediate-acting components in one formulation. Although the basal bolus insulin regimen is considered by many as “the golden standard” in reaching goals of glycemic control, proper use of intensified insulin regimens, such as basal bolus or premixed, will result in similar HbA1c reduction, hypoglycemic events, and weight gain. At the same number of daily insulin injections (2 shots/day), the premixed regimen is associated with a significant 0.2 % HbA1c decrease, as compared with the basal plus regimen (one shot of long-acting plus one shot of short-acting insulin). The choice of insulin regimen should consider the preferences, and resources of the individual and the family for adapting treatment to the patient needs. At last, the process of insulin initiation and intensification in type 2 diabetes must be carried out in the context of patient safety, minimizing the risk of hypoglycemia, weight gain, and injection burden.
Literatur
1.
2.
Zurück zum Zitat J.A. Greene, K.R. Riggs, Why is there no generic insulin? Historical origins of a modern problem. N. Engl. J. Med. 372, 1171–1175 (2015)CrossRefPubMed J.A. Greene, K.R. Riggs, Why is there no generic insulin? Historical origins of a modern problem. N. Engl. J. Med. 372, 1171–1175 (2015)CrossRefPubMed
3.
Zurück zum Zitat D. Pournaras, C. le Roux, Type 2 diabetes: multimodal treatment of a complex disease. Lancet 386, 936–937 (2015)CrossRefPubMed D. Pournaras, C. le Roux, Type 2 diabetes: multimodal treatment of a complex disease. Lancet 386, 936–937 (2015)CrossRefPubMed
4.
Zurück zum Zitat E.W. Gregg, X. Zhuo, Y.J. Cheng, A.L. AlbrighL, K.M. Narayan, T.J. Thompson, Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985–2011: a modelling study. Lancet Diabetes Endocrinol. 2, 867–874 (2014)CrossRefPubMed E.W. Gregg, X. Zhuo, Y.J. Cheng, A.L. AlbrighL, K.M. Narayan, T.J. Thompson, Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985–2011: a modelling study. Lancet Diabetes Endocrinol. 2, 867–874 (2014)CrossRefPubMed
5.
Zurück zum Zitat American Diabetes Association, 7. Approaches to glycemic treatment. Diabetes Care 38(Suppl. 1), S52–S59 (2016) American Diabetes Association, 7. Approaches to glycemic treatment. Diabetes Care 38(Suppl. 1), S52–S59 (2016)
6.
Zurück zum Zitat L.W. Turner, D. Nartey, R.S. Stafford, S. Singh, G.C. Alexander, Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012. Diabetes Care 37, 985–992 (2014)CrossRefPubMedPubMedCentral L.W. Turner, D. Nartey, R.S. Stafford, S. Singh, G.C. Alexander, Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012. Diabetes Care 37, 985–992 (2014)CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat J. Luo, J. Avorn, A.S. Kesselheim, Trends in medicaid reimbursements for insulin from 1991 through 2014. JAMA Intern. Med. 175(10), 1681–1686 (2015)CrossRefPubMed J. Luo, J. Avorn, A.S. Kesselheim, Trends in medicaid reimbursements for insulin from 1991 through 2014. JAMA Intern. Med. 175(10), 1681–1686 (2015)CrossRefPubMed
9.
Zurück zum Zitat D. Giugliano, M. Petrizzo, M. Maiorino, G. Bellastella, K. Esposito, Comment on Grunberger ``Insulin analogs-are they worth it? Yes!” Diabetes Care 2014;37:1767–1770 and Davidson ``Insulin analogs-is there a compelling case to use them? No!” Diabetes Care 2014;37:1771–1774. Diabetes Care 37, e229–e230 (2014)CrossRefPubMed D. Giugliano, M. Petrizzo, M. Maiorino, G. Bellastella, K. Esposito, Comment on Grunberger ``Insulin analogs-are they worth it? Yes!” Diabetes Care 2014;37:1767–1770 and Davidson ``Insulin analogs-is there a compelling case to use them? No!” Diabetes Care 2014;37:1771–1774. Diabetes Care 37, e229–e230 (2014)CrossRefPubMed
10.
Zurück zum Zitat K. Esposito, P. Chiodini, G. Bellastella, M.I. Maiorino, D. Giugliano, Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients. Diabetes Obes. Metab. 14, 228–233 (2012)CrossRefPubMed K. Esposito, P. Chiodini, G. Bellastella, M.I. Maiorino, D. Giugliano, Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients. Diabetes Obes. Metab. 14, 228–233 (2012)CrossRefPubMed
11.
Zurück zum Zitat P. de Pablos-Velasco, K.G. Parhofer, C. Bradley, E. Eschwège, L. Gönder-Frederick, P. Maheux, I. Wood, D. Simon, Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin. Endocrinol. 80, 47–56 (2014)CrossRef P. de Pablos-Velasco, K.G. Parhofer, C. Bradley, E. Eschwège, L. Gönder-Frederick, P. Maheux, I. Wood, D. Simon, Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin. Endocrinol. 80, 47–56 (2014)CrossRef
12.
Zurück zum Zitat D. Giugliano, M.I. Maiorino, G. Bellastella, P. Chiodini, K. Esposito, Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diabetes Res. Clin. Pract. 92, 1–10 (2011)CrossRefPubMed D. Giugliano, M.I. Maiorino, G. Bellastella, P. Chiodini, K. Esposito, Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diabetes Res. Clin. Pract. 92, 1–10 (2011)CrossRefPubMed
13.
Zurück zum Zitat B.T. Blak, H.T. Smith, M. Hards, A. Maguire, V. Gimeno, A retrospective database study of insulin initiation in patients with type 2 diabetes in UK primary care. Diabet. Med. 29, e191–e198 (2012)CrossRefPubMed B.T. Blak, H.T. Smith, M. Hards, A. Maguire, V. Gimeno, A retrospective database study of insulin initiation in patients with type 2 diabetes in UK primary care. Diabet. Med. 29, e191–e198 (2012)CrossRefPubMed
14.
Zurück zum Zitat D. Giugliano, M.I. Maiorino, G. Bellastella, P. Chiodini, A. Ceriello, K. Esposito, Efficacy of insulin analogs in achieving the hemoglobin A1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 34, 510–517 (2011)CrossRefPubMedPubMedCentral D. Giugliano, M.I. Maiorino, G. Bellastella, P. Chiodini, A. Ceriello, K. Esposito, Efficacy of insulin analogs in achieving the hemoglobin A1c target of < 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 34, 510–517 (2011)CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat J.L. Li, W. Jia, J. Weng, Glycemic control in insulinized type 2 diabetes patients in China: one-year results from IDMPS. American Diabetes Association 69th Scientific Sessions, New Orleans, 5–9 June 2009 J.L. Li, W. Jia, J. Weng, Glycemic control in insulinized type 2 diabetes patients in China: one-year results from IDMPS. American Diabetes Association 69th Scientific Sessions, New Orleans, 5–9 June 2009
16.
Zurück zum Zitat P.D. Home, M.-P. Dain, N. Freemantle, R. Kawamori, M. Pfohl, S. Brette, V. Pilorget, W.A. Scherbaum, G. Vespasiani, M. Vincent, B. Balkau, Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Res. Clin. Pract. 108, 250–359 (2015)CrossRef P.D. Home, M.-P. Dain, N. Freemantle, R. Kawamori, M. Pfohl, S. Brette, V. Pilorget, W.A. Scherbaum, G. Vespasiani, M. Vincent, B. Balkau, Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Res. Clin. Pract. 108, 250–359 (2015)CrossRef
17.
Zurück zum Zitat S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), European Association for the Study of Diabetes (EASD), Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35, 1364–1379 (2012)CrossRefPubMedPubMedCentral S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), European Association for the Study of Diabetes (EASD), Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35, 1364–1379 (2012)CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat M.R. Lankisch, K.C. Ferlinz, J.L. Leahy, W.A. Scherbaum, Orals Plus Apidra and LANTUS (OPAL) Study Group, Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes. Metab. 10, 1178–1185 (2008)PubMed M.R. Lankisch, K.C. Ferlinz, J.L. Leahy, W.A. Scherbaum, Orals Plus Apidra and LANTUS (OPAL) Study Group, Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes. Metab. 10, 1178–1185 (2008)PubMed
19.
Zurück zum Zitat M.B. Davidson, P. Raskin, R.J. Tanenberg, A. Vlajnic, P. Hollander, A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr. Pract. 17, 395–403 (2001)CrossRef M.B. Davidson, P. Raskin, R.J. Tanenberg, A. Vlajnic, P. Hollander, A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr. Pract. 17, 395–403 (2001)CrossRef
20.
Zurück zum Zitat A.J. Garber, J. Wahlen, T. Wahl, P. Bressler, R. Braceras, E. Allen, R. Jain, Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1–2–3 study). Diabetes Obes. Metab. 8, 58–66 (2006)CrossRefPubMed A.J. Garber, J. Wahlen, T. Wahl, P. Bressler, R. Braceras, E. Allen, R. Jain, Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1–2–3 study). Diabetes Obes. Metab. 8, 58–66 (2006)CrossRefPubMed
21.
Zurück zum Zitat O. Mosenzon, I. Raz, Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom? Diabetes Care 36(Suppl 2), S212–S218 (2013)CrossRefPubMedPubMedCentral O. Mosenzon, I. Raz, Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom? Diabetes Care 36(Suppl 2), S212–S218 (2013)CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat C. Wang, J. Mamza, I. Idris, Biphasic vs basal bolus insulin regimen in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet. Med. 32, 585–594 (2015)CrossRefPubMed C. Wang, J. Mamza, I. Idris, Biphasic vs basal bolus insulin regimen in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet. Med. 32, 585–594 (2015)CrossRefPubMed
23.
Zurück zum Zitat D. Giugliano, P. Chiodini, M.I. Maiorino, G. Bellastella, K. Esposito, Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine 51, 417–428 (2016)CrossRefPubMed D. Giugliano, P. Chiodini, M.I. Maiorino, G. Bellastella, K. Esposito, Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine 51, 417–428 (2016)CrossRefPubMed
24.
Zurück zum Zitat J. Vora, N. Cohen, M. Evans, A. Hockey, J. Speight, C. Whately-Smith, Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape). Diabetes Obes. Metab. 17, 1133–1141 (2015)CrossRefPubMed J. Vora, N. Cohen, M. Evans, A. Hockey, J. Speight, C. Whately-Smith, Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape). Diabetes Obes. Metab. 17, 1133–1141 (2015)CrossRefPubMed
25.
Zurück zum Zitat S.-M. Jin, J.H. Kim, K.W. Mim, J.H. Lee, K.J. Ahn, J.H. Park, H.C. Jang, S.W. Park, K.W. Lee, K.C. Won, Y.-I. Kim, C.H. Chung, T.S. Park, J.-H. Lee, M.-K. Lee, Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: a 24-week randomized non-inferiority trial. J. Diabetes (2015). doi:10.1111/1753-0407.12312 S.-M. Jin, J.H. Kim, K.W. Mim, J.H. Lee, K.J. Ahn, J.H. Park, H.C. Jang, S.W. Park, K.W. Lee, K.C. Won, Y.-I. Kim, C.H. Chung, T.S. Park, J.-H. Lee, M.-K. Lee, Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: a 24-week randomized non-inferiority trial. J. Diabetes (2015). doi:10.​1111/​1753-0407.​12312
26.
Zurück zum Zitat T. Heise, L. Heinemann, U. Hövelmann, B. Brauns, L. Nosek, H.L. Haahr, K.J. Olsen, Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy. Diabetes Care 32, 1431–1433 (2009)CrossRefPubMedPubMedCentral T. Heise, L. Heinemann, U. Hövelmann, B. Brauns, L. Nosek, H.L. Haahr, K.J. Olsen, Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy. Diabetes Care 32, 1431–1433 (2009)CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat A. Tsapas, T. Karagiannis, E. Bekiari, Premixed insulin regimens for type 2 diabetes. Endocrine 51, 387–389 (2016)CrossRefPubMed A. Tsapas, T. Karagiannis, E. Bekiari, Premixed insulin regimens for type 2 diabetes. Endocrine 51, 387–389 (2016)CrossRefPubMed
28.
Zurück zum Zitat F.J. Tinahones, J.L. Gross, A. Onaca, S. Cleall, A. Rodríguez, Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Diabetes Obes. Metab. 16, 963–970 (2014)CrossRefPubMedPubMedCentral F.J. Tinahones, J.L. Gross, A. Onaca, S. Cleall, A. Rodríguez, Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial. Diabetes Obes. Metab. 16, 963–970 (2014)CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat R. Malek, F. Ajili, S.H. Assaad-Khalil, A. Shinde, J.W. Chen, E. Van den Berg, Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: results of a 50-week randomized clinical trial of stepwise insulin intensification. Diabetes Metab. 41, 223–230 (2015)CrossRefPubMed R. Malek, F. Ajili, S.H. Assaad-Khalil, A. Shinde, J.W. Chen, E. Van den Berg, Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: results of a 50-week randomized clinical trial of stepwise insulin intensification. Diabetes Metab. 41, 223–230 (2015)CrossRefPubMed
30.
Zurück zum Zitat D. Giugliano, M. Tracz, S. Shah, A. Calle-Pascual, C. Mistodie, R. Duarte, R. Sari, V. Woo, A.O. Jiletcovici, J. Deinhard, S.A. Wille, J. Kiljanski, Initiation and gradual intensification of premixed insulin lispro therapy versus basal ± mealtime insulin in patients with type 2 diabetes eating light breakfasts. Diabetes Care 37, 372–380 (2014)CrossRefPubMed D. Giugliano, M. Tracz, S. Shah, A. Calle-Pascual, C. Mistodie, R. Duarte, R. Sari, V. Woo, A.O. Jiletcovici, J. Deinhard, S.A. Wille, J. Kiljanski, Initiation and gradual intensification of premixed insulin lispro therapy versus basal ± mealtime insulin in patients with type 2 diabetes eating light breakfasts. Diabetes Care 37, 372–380 (2014)CrossRefPubMed
31.
Zurück zum Zitat M.C. Riddle, J. Rosenstock, A. Vlajnic, L. Gao, Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes. Metab. 16, 396–402 (2014)CrossRefPubMed M.C. Riddle, J. Rosenstock, A. Vlajnic, L. Gao, Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. Diabetes Obes. Metab. 16, 396–402 (2014)CrossRefPubMed
32.
Zurück zum Zitat W. Jia, X. Xiao, Q. Ji, K.-J. Ahn, L.-M. Chuang, Y. Bao, C. Pang, L. Chen, F. Gao, Y. Tu, P. Li, J. Yang, Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. Lancet Diabetes Endocrinol. 3, 254–262 (2015)CrossRefPubMed W. Jia, X. Xiao, Q. Ji, K.-J. Ahn, L.-M. Chuang, Y. Bao, C. Pang, L. Chen, F. Gao, Y. Tu, P. Li, J. Yang, Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. Lancet Diabetes Endocrinol. 3, 254–262 (2015)CrossRefPubMed
33.
Zurück zum Zitat D. Giugliano, M.I. Maiorino, G. Bellastella, M. Petrizzo, A. Ceriello, S. Genovese, K. Esposito, Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither? Endocrine 50, 56–60 (2015)CrossRefPubMed D. Giugliano, M.I. Maiorino, G. Bellastella, M. Petrizzo, A. Ceriello, S. Genovese, K. Esposito, Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither? Endocrine 50, 56–60 (2015)CrossRefPubMed
34.
Zurück zum Zitat G. Dieuzeide, L.M. Chuang, A. Almaghamsi, A. Zilov, J.W. Chen, F.J. Lavalle-González, Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study. Prim. Care Diabetes 8, 111–117 (2014)CrossRefPubMed G. Dieuzeide, L.M. Chuang, A. Almaghamsi, A. Zilov, J.W. Chen, F.J. Lavalle-González, Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study. Prim. Care Diabetes 8, 111–117 (2014)CrossRefPubMed
35.
Zurück zum Zitat C. Mathieu, F. Storms, J. Tits, T.F. Veneman, I.M. Colin, Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study. Acta Clin. Belg. 68, 28–33 (2013)CrossRefPubMed C. Mathieu, F. Storms, J. Tits, T.F. Veneman, I.M. Colin, Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study. Acta Clin. Belg. 68, 28–33 (2013)CrossRefPubMed
36.
Zurück zum Zitat C.J. Currie, M. Peyrot, C.L. Morgan, C.D. Poole, S. Jenkins-Jones, R.R. Rubin, C.M. Burton, M. Evans, The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 35, 1279–1284 (2012)CrossRefPubMedPubMedCentral C.J. Currie, M. Peyrot, C.L. Morgan, C.D. Poole, S. Jenkins-Jones, R.R. Rubin, C.M. Burton, M. Evans, The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care 35, 1279–1284 (2012)CrossRefPubMedPubMedCentral
Metadaten
Titel
Premixed insulin regimens in type 2 diabetes: pros
verfasst von
Maria Ida Maiorino
Giuseppe Bellastella
Katherine Esposito
Dario Giugliano
Publikationsdatum
22.03.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0917-6

Weitere Artikel der Ausgabe 1/2017

Endocrine 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.